BETA: Please send your feedback!

Celldex Therapeutics

CLDX:NAS

Biotechnology

$0
SMALL cap
$1.61 (-0.05%)
-0.31%
since start of 2020
-0.44
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

About

Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
 website

Headquarters

Suite 220
53 Frontage Road
Perryville III Building
Hampton, NJ 08827
1.908.454.7120

Executives

Name Title Gender
Thomas Andrew Davis, MD Chief Medical Officer & Executive Vice President Male
Avery W. Catlin, MBA, CPA CFO, Secretary, Treasurer & Senior Vice President Male
Larry Ellberger Chairman Male
Anthony S. Marucci, MBA President, Chief Executive Officer & Director Male
Tibor Keler, PhD Chief Scientific Officer & Executive VP Male
Sarah Boylan Cavanaugh VP-Investor Relations & Corporate Communications Female
Theresa M. LaVallee, PhD Senior VP-Regulatory & Precision Medicine Female

Mindful Investing Summary

  • —
  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint
    — N/A
  • Pollution Prevention
    — N/A
  • Water Conservation
    — N/A
  • Data & Privacy Protection
    — N/A
  • Consumer Health, Wellness & Safety
    — N/A
  • Employee Ownership, Satisfaction, Benefits & Pay
    — N/A
  • Workplace Health and Safety
    — N/A
  • Integrity of Corporate Governance
    — N/A
  • Ethical Practices
    — N/A
  • Usage of Conflict Materials
    — N/A
  • Forced Labor
    — N/A
  • Diversity of Corporate Leadership
    2 N/A

Celldex Therapeutics - Competitors and Related Companies

How Celldex Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.

Celldex Therapeutics

CLDX:NAS

Biotechnology

$0
SMALL cap
$1.61 (-0.05%)
-0.31%
since start of 2020
-0.44
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Northwest Biotherapeutics

NWBO:OTC

Biotechnology

$0
MICRO cap
$0.15 (-0.01%)
-0.38%
since start of 2020
-3.80
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Seattle Genetics

SGEN:NAS

Biotechnology

$19.16bn
MID cap
$111.24 (-4.14%)
-0.06%
since start of 2020
-114.67
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Amgen

AMGN:NAS

Biotechnology

$116.67bn
MEGA cap
$197.81 (-4.92%)
-0.21%
since start of 2020
15.28
  • 5
  • 5
  • 2
  • 5
  • —
  • 1
  • 5
  • 4
  • 1
  • —
  • —
  • 5
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Bristol-Myers Squibb

BMY:NYS

Pharmaceuticals: Major

$124.03bn
MEGA cap
$54.82 (-0.92%)
-0.16%
since start of 2020
24.91
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

GlaxoSmithKline

GSK-GB:LON

Pharmaceuticals: Major

$92.69bn
MEGA cap
$37.22 (-0.67%)
-0.22%
since start of 2020
15.60
  • 1
  • 3
  • 1
  • —
  • —
  • 3
  • 1
  • 3
  • —
  • —
  • —
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5